GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bone Biologics Corp (NAS:BBLG) » Definitions » 9-Day RSI

Bone Biologics (Bone Biologics) 9-Day RSI : 28.08 (As of Apr. 25, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Bone Biologics 9-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2024-04-25), Bone Biologics's 9-Day RSI is 28.08.

The industry rank for Bone Biologics's 9-Day RSI or its related term are showing as below:

BBLG's 9-Day RSI is ranked better than
89.72% of 885 companies
in the Medical Devices & Instruments industry
Industry Median: 46.1 vs BBLG: 28.08

Competitive Comparison of Bone Biologics's 9-Day RSI

For the Medical Devices subindustry, Bone Biologics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bone Biologics's 9-Day RSI Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bone Biologics's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Bone Biologics's 9-Day RSI falls into.



Bone Biologics  (NAS:BBLG) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bone Biologics  (NAS:BBLG) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.


Bone Biologics 9-Day RSI Related Terms

Thank you for viewing the detailed overview of Bone Biologics's 9-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Bone Biologics (Bone Biologics) Business Description

Traded in Other Exchanges
N/A
Address
2 Burlington Woods Drive, Suite 100, Burlington, MA, USA, 01803
Bone Biologics Corp is a healthcare solutions provider based in the United States. As a biotechnology firm, it engages its efforts in developing therapeutics to aid bone regeneration. The company's portfolio comprises its lead product, NELL-1, which is a bone void filler. Bone Biologics' technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine.
Executives
Deina H Walsh officer: Chief Financial Officer 175, MAY STREET, EDISON NJ 08837
Jeff Frelick officer: Chief Operating Officer 1 FOX RUN LANE,, LEXINGTON MA 02420
Knight Insurance Company, Ltd 10 percent owner 4751 WILSHIRE BLVD.,, SUITE 111, LOS ANGELES CA 90010
Siddhesh Rajendra Angle director 481 MONMOUTH ST, UNIT G,, JERSEY CITY NJ 07302
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
Don Hankey director, 10 percent owner, officer: Chairman of the Board 4751 WILSHIRE BLVD., SUITE 110, LOS ANGELES CA 90010
Bret Hankey director 4751 WILSHIRE BLVD. #110, LOS ANGELES CA 90010
Hankey Capital, Llc 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Don Hankey Trust 10 percent owner 4751 WILSHIRE BLVD., #110, LOS ANGELES CA 90010
Amir F Heshmatpour 10 percent owner 269 S. BEVERLY DRIVE, STE #1600, BEVERLY HILLS CA 90212
Musculoskeletal Transplant Foundation, Inc. director 175 MAY STREET, SUITE 300, EDISON NJ 08837
Benjamin Wu director 2740 LORAIN ROAD, SAN MARINO CA 91108
La Neve Stephen R. director, officer: CEO and President 106 MCCOOL BLVD, WEST CHESTER PA 19380
George A Oram director 12 EDGEMONT LANE, BEDMINSTER NJ 07921
Jim Delshad director 132 S. MAPLE DR., BEVERLY HILLS CA 90212